# Avenzo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avenzo-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.avenzotx.com
- Total disclosed funding: $402M
- Latest round: Series B (Aug 22, 2025)
- Investors on record: 13

## About

Founded in 2022 and based in California, US, Avenzo Therapeutics, Inc. operates as a clinical-stage biotechnology company that develops and offers an oncology platform intended to develop novel treatments for underserved cancers. In September 2025, Avenzo Therapeutics, Inc. raised USD 60 million in series B funding co-led by new investors OrbiMed Advisors and SR One, with participation from returning investors Foresite Capital, Lilly Asia Ventures, Surveyor Capital, New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital Alternatives, INCE Capital, TF Capital, Delos Capital Management, and Quan Capital. Other unspecified investors also participated in the round.  

The firm develops and provides oncology therapies to address cancers with high unmet medical needs. The firm’s lead program, AVZO-021, targets cyclin-dependent kinase 2 (CDK2), to treat various cancers, including HR+ breast cancer, ovarian cancer, and small-cell lung cancer. The platform selectively inhibits CDK2 to overcome resistance to existing therapies and improve treatment outcomes.

The company will use the September 2025 funding to support the development of its oncology drug candidates, including AVZO-021, AVZO-023, AVZO-1418, and AVZO-103.

## Funding rounds

- Series B, Aug 22, 2025, $47M — New Enterprise Associates, OrbiMed Advisors, Sofinnova Investments, SR One, Lilly Asia Ventures, Surveyor Capital, Foresite Capital, Delos Capital, Sands Capital Alternatives, TF Capital, Quan Capital, INCE Capital, Deep Track Capital
- Series A, Nov 19, 2024, $163M — Lilly Asia Ventures, Surveyor Capital, Foresite Capital
- Series A, Mar 26, 2024, $192M — New Enterprise Associates, Sofinnova Investments, Delos Capital, Sands Capital Alternatives, TF Capital, Quan Capital, INCE Capital, Deep Track Capital

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B
- Delos Capital (https://capitalatlas.ai/funds/delos-capital) — Series A, Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series A, Series B
- TF Capital — Series A, Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A, Series B
- INCE Capital (https://capitalatlas.ai/funds/ince-capital) — Series A, Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Surveyor Capital — Series A, Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B